|Bid||18.80 x 800|
|Ask||0.00 x 900|
|Day's Range||20.54 - 21.94|
|52 Week Range||20.54 - 56.59|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||49.67|
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that results of LOTIS-2, a multicenter, open-label, single-arm Phase 2 clinical trial evaluating the safety and efficacy of single-agent ZYNLONTA™ in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) following two or more systemic treatments, have been published online in The Lancet Oncology.
This morning, we issued a press release announcing our first-quarter 2021 financial results and business update. On today's call, Chris Martin, chief executive officer; Jennifer Herron, our chief commercial officer; Jay Feingold, chief medical officer; and Jenn Creel, chief financial officer, will discuss recent business highlights and review our first-quarter 2021 financial results before opening the call for questions.
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today reported financial results for the first quarter ended March 31, 2021 and provided business updates.